Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Steven E. Nissen(Cleveland Clinic), Kathy Wolski(Cleveland Clinic)
Cited by 4,652
Related Papers
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
|New England Journal of Medicine|2016|846
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
|Circulation|2018|712
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
|Circulation|2014|702
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
|Journal of the American College of Cardiology|2014|596